AstraZeneca PLC · LSE:AZN
AstraZeneca — Exane Pharma Conference Paris 2004
20 slides from AstraZeneca's conference presentation, May 2004
Slide 1: AstraZeneca
AstraZeneca Jon Symonds May 2004
Slide 2: Headline results Q1 04
Headline results Q1 04 Q1 04 Q1 03 Actual CER* $m $m growth growth Sales 5,074 4,735 +7% -1% Operating profit 1,079 1,272 -15% -20% Profit before Tax 1,108 1,293 -14% -20% EPS (pre-excep) $0.47 $0.54 -13% -19% *Constant exchange rates 2
Slide 3: Successful portfolio transformation
Successful portfolio transformation Exanta® Crestor® 2001 2003 Iressa® Prilosec® Faslodex® Zestril® Symbicort® Base Plendil® Nexium® Expiry Nolvadex® Casodex® Arimidex® Growth Zomig® Seroquel® Atacand® $16.2 billion $18.8 billion +$2.6 billion 3
Slide 4: AstraZeneca strategy
AstraZeneca strategy 1999 2004 2008+ Deliver Top-tier financial performance Full potential of growth portfolio Drive Productivity for competitive Sustainable Platform for advantage growth for growth Expand long term Next wave of development projects In-house discovery External collaboration Broaden
Slide 5: 2004 priorities
2004 priorities Continue to build Crestor® into megabrand Drive Oncology portfolio Progress to US market leadership for Nexium® and Seroquel® First launches for Exanta® and register chronic claims Advance development projects Continuous improvement in productivity 2004 EPS range in range of $2. 00 t
Slide 6: Crestor
Crestor® First launch Feb 03 (Netherlands) US launch Sept 03 Crestor® profile • Lowers LDL-C by up to 63% across the dose range • Gets more patients to goal • HDL-C raising is maintained across dose range • Well tolerated, safety profile comparable to other marketed statins Approved in over 50 marke
Slide 7: Crestor: early launch markets
Crestor®: early launch markets 12 Canada 10 10.6 Netherlands 8 9.0 %TRx share 6 4.5 USA 4 2.9 France UK 2 1.8 0 k1 k3 k5 k7 k9 1 3 5 7 9 1 3 5 7 9 1 3 5 7 9 1 k1 k1 k1 K1 k1 k2 k2 k2 k2 k2 k3 k3 k3 k3 k3 k4 W W W W W W W W W W W W W W W W W W W W W Canada Netherlands UK US France Share of C10A1, Sta
Slide 8: Crestor: US launch dynamic share
Crestor®: US launch dynamic share 50 45 % Share of Dynamic Patient Opportunities 40 35 30 25 20 16.9% 15 10 5 0 wk1 wk3 wk5 wk7 wk9 w k 11 w k 13 w k 15 w k 17 w k 19 w k 21 w k 23 Lipitor Zocor CRESTOR Lovastatin Total Pravachol Source: Verispan Instant VectorOne; Market = USC 32110 8
Slide 9: Oncology
Oncology A Global leader • FY 03 sales +8% $2.7 billion (+26% ex. Nolvadex®) Casodex® - class leader (+22% $854 million) • Early prostate cancer Faslodex® - first in class ($77 million) • EU launches from 2Q 2004 Iressa® - first in class ($228 million) • Japan $101 million • US $102 million - >42,00
Slide 10: Arimidex – Strong Growth
US$000’s 0 10,000 20,000 30,000 40,000 50,000 Dec-01 60,000 Jan-02 Feb-02 Mar-02 Apr-02 May-02 Continues Jun-02 Jul-02 Aug-02 Sep-02 Oct-02 ! Nov-02 Dec-02 Jan-03 Feb-03 Mar-03 Apr-03 ATAC 2nd analysis May-03 Jun-03 Arimidex® – Strong Growth Jul-03 Aug-03 Sep-03 10 Oct-03 MA17 Nov-03 Dec-03 Jan-04 l
Slide 11: Arimidex volume share: significant opportunity for continued growth
% volume share 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% " Ja n- 0 # Fe 2 b- 0 M 2 ar -0 88% #"$ Ap 2 r- 0 M 2 ay -0 2 ATAC data Ju n- #" %& 02 ' Ju l -0 Au 2 ! g- 0 # Se 2 p- 0 O 2 ct- 0 # ()# No 2 v-0 De 2 (% c- 0 Ja 2 Continued Growth n- ! 0 Fe 3 b- 0 M 3 ar -0 Ap 3 r- 0 M 3 ay -0 3 Ju n- 03 Ju
Slide 12: Iressa survival: Promising a better future for patients
Iressa® survival: Promising a better future for patients 1.0 0.8 ~ 30% survival at 1 year Massarelli et al 3rd & 4th line Reference data 0.6 Iressa® IDEAL 1 Iressa® IDEAL 2 Iressa® EAP survival USA 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Months from randomization 12
Slide 13: Seroquel
Seroquel® Full year sales $1,487 million; up 27% CER Q1 04 sales $448 million; down 2% CER The only leading (top 3) atypical antipsychotic to grow market share* Bipolar mania approved in US and EU Bipolar depression data (BOLDER Study) – APA ‘04 *Source: IMS Health, IMS MIDAS 2003 13
Slide 14: Seroquel: US NRx in anti-psychotic market
0% 5% 10% 15% 20% 25% 30% 35% Jan-00 Feb-00 Mar-00 Market share Apr-00 May-00 Jun-00 Jul-00 Aug-00 market Sep-00 Oct-00 Nov-00 Dec-00 Jan-01 Feb-01 Mar-01 Apr-01 May-01 Jun-01 Jul-01 Aug-01 Sep-01 Oct-01 Nov-01 Dec-01 Jan-02 Feb-02 Mar-02 Apr-02 May-02 Jun-02 Jul-02 Aug-02 Sep-02 Oct-02 Nov-02 Sourc
Slide 15: Nexium US TRx PPI market share
Nexium® US TRx PPI market share 60% Total Prescription Market Share (PPI) 50% 40% 30% 20% 10% 0% Ja 0 Ja 1 Ja 2 Ja 3 M 0 M 00 Se 0 N 0 M 1 M 01 Se 01 N 1 M 2 M 02 S 02 No 2 M 3 M 03 S 3 No 3 M 4 4 Ju 0 1 2 Ju 3 -0 -0 0 0 -0 0 -0 l-0 0 0 -0 0 0 -0 -0 0 -0 l-0 -0 0 n- - n- - l- n- - l- v- n- - v- n- p
Slide 16: US PPI Market - TRx Growth Trends
US PPI Market - TRx Growth Trends* Q103 Q203 Q303 Q403 Q104 30% 26% 19% 20% 14% 14% 13% 12% 10% 10% 1% 0% -2% -10% -20% -30% -40% -35% -50% -44% PPI Omeprazole PPI ex-omep Nexium *TRx growth rates versus same period in the prior year 16
Slide 17: Symbicort
Symbicort® $m 200 180 COPD approved in 160 42 countries 140 Single Therapy EU 120 100 filing submitted 80 9 December 2003 60 Phase III studies 40 underway in US 20 0 Q1 02 Q1 03 Q1 04 17
Slide 18: Exanta - Oral Direct Thrombin Inhibitor
Exanta® - Oral Direct Thrombin Inhibitor Prompt onset and offset of anticoagulation Wider therapeutic margin than warfarin Predictable pharmacokinetics Low potential for food and drug interactions No dose adjustment No coagulation monitoring Elevation of ALAT in some patients OS indication (EU) • Fi
Slide 19: 2004 Outlook
2004 Outlook Top-tier financial performance overriding objective • 2004 target EPS $2.00 - $2.15 Sales • Mid-teen growth (including currency) Costs and margins • Further gross margin improvement • SG&A / R&D high teens (including currency) • Currency offset on operating margin Key sensitivities • Cr
Slide 20: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with